
BX-471

产品编号: D51630

CAS: 217645-70-0

分子式: C₂₁H₂₄ClFN₄O₃

纯度: ≥98%

InChi: InChi=1S/C₂₁H₂₄ClFN₄O₃/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)/t14-/m1/s1

InChi Key: XQYASZNUFDVMFH-CQSZACIVSA-N

Smiles: C[C@@H]1CN(CCN1C(=O)COC1C=CC(Cl)=CC=1NC(N)=O)CC1C=CC(F)=CC=1

外观: 固体粉末

作用通路: CCR

溶解性: Soluble in DMSO, not in water

保存条件: Store in dry, dark place for one year.

产品介绍: BX-471, also known as ZK-811752, is a potent, selective non-peptide CCR1 antagonist (K_i = 1 nM for human CCR1). BX-471 exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX-471 was developed Berlex and its parent company, Schering AG. BX-471 is the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases.